Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 CHF | +0.77% | -8.16% | +87.11% |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 34.58 | 55.01 | 66.24 | 63.13 | 53.72 | 128.3 |
Enterprise Value (EV) 1 | 16.25 | 36.64 | 40.27 | 36.72 | 31.63 | 116.3 |
P/E ratio | -1.72 x | -3.45 x | -4.26 x | -8.37 x | -3.41 x | -9.18 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 48.4 x | 21.5 x | 16.4 x | 4.57 x | 2.99 x | 3.82 x |
EV / Revenue | 22.7 x | 14.3 x | 9.97 x | 2.66 x | 1.76 x | 3.46 x |
EV / EBITDA | -1.38 x | -4.08 x | -4.25 x | -5.79 x | -2.85 x | -17.7 x |
EV / FCF | -2.08 x | -5.99 x | -5.29 x | 7.01 x | -4.65 x | -16 x |
FCF Yield | -48.1% | -16.7% | -18.9% | 14.3% | -21.5% | -6.27% |
Price to Book | 0.45 x | 0.71 x | 0.78 x | 0.82 x | 0.78 x | 2.26 x |
Nbr of stocks (in thousands) | 15,035 | 22,453 | 32,794 | 32,794 | 36,544 | 36,759 |
Reference price 2 | 2.300 | 2.450 | 2.020 | 1.925 | 1.470 | 3.490 |
Announcement Date | 12/04/19 | 27/03/20 | 19/03/21 | 05/04/22 | 15/03/23 | 12/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 0.715 | 2.561 | 4.039 | 13.82 | 17.99 | 33.56 |
EBITDA 1 | -11.78 | -8.972 | -9.484 | -6.341 | -11.1 | -6.561 |
EBIT 1 | -13.73 | -11.39 | -11.79 | -8.767 | -13.45 | -8.657 |
Operating Margin | -1,919.86% | -444.83% | -291.83% | -63.46% | -74.76% | -25.79% |
Earnings before Tax (EBT) 1 | -13.81 | -11.82 | -12.09 | -9.554 | -15.99 | -13.35 |
Net income 1 | -11.69 | -11.25 | -11.52 | -7.541 | -14.6 | -13.73 |
Net margin | -1,635.38% | -439.36% | -285.22% | -54.59% | -81.15% | -40.9% |
EPS 2 | -1.340 | -0.7111 | -0.4737 | -0.2300 | -0.4305 | -0.3800 |
Free Cash Flow 1 | -7.812 | -6.116 | -7.605 | 5.237 | -6.797 | -7.29 |
FCF margin | -1,092.6% | -238.81% | -188.29% | 37.91% | -37.79% | -21.72% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 12/04/19 | 27/03/20 | 19/03/21 | 05/04/22 | 15/03/23 | 12/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 18.3 | 18.4 | 26 | 26.4 | 22.1 | 12 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -7.81 | -6.12 | -7.6 | 5.24 | -6.8 | -7.29 |
ROE (net income / shareholders' equity) | -15.6% | -14.6% | -14.2% | -9.33% | -20% | -21.9% |
ROA (Net income/ Total Assets) | -9.98% | -8.2% | -8.09% | -5.9% | -9.64% | -7.01% |
Assets 1 | 117.1 | 137.2 | 142.5 | 127.8 | 151.3 | 195.9 |
Book Value Per Share 2 | 5.080 | 3.470 | 2.580 | 2.350 | 1.880 | 1.540 |
Cash Flow per Share 2 | 1.220 | 0.9300 | 0.8700 | 0.8700 | 0.6600 | 0.3900 |
Capex 1 | 0.06 | 0.09 | 0.06 | 0.3 | 0.39 | 0.32 |
Capex / Sales | 8.95% | 3.32% | 1.51% | 2.2% | 2.19% | 0.94% |
Announcement Date | 12/04/19 | 27/03/20 | 19/03/21 | 05/04/22 | 15/03/23 | 12/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+87.11% | 260M | |
-1.40% | 104B | |
+6.86% | 97.47B | |
+5.71% | 22.25B | |
-12.63% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.25% | 16.36B | |
+7.44% | 14.39B | |
+37.50% | 12.37B |
- Stock Market
- Equities
- KURN Stock
- Financials Kuros Biosciences AG